GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Pasireotide

Company
University of Colorado, Denver
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
5 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

5 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Pasireotide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06295952

    A Study of Pasireotide in People With Prolactinoma

    Not yet reported Memorial Sloan Kettering Cancer Center 10 participants Est. completion 2027-02 7 sites Stand-alone
    Other conditions: Prolactin-Producing Pituitary Tumor
    View official trial listing →
  • Recruiting NCT NCT06456359

    Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

    Not yet reported University Hospital Heidelberg 28 participants Est. completion 2028-10 4 sites Stand-alone
    Other conditions: Desmoplastic Small Round Cell Tumor, Synovial Sarcoma
    View official trial listing →
  • Recruiting NCT NCT06597383

    The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly

    IRCCS San Raffaele 100 participants Est. completion 2024-11 1 site
    Other conditions: Acromegaly
    View official trial listing →
  • Recruiting NCT NCT06784752

    Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

    Not yet reported Novartis Pharmaceuticals 240 participants Est. completion 2034-01-23 65 sites
    Other conditions: Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
    View official trial listing →
  • Recruiting NCT NCT07179926

    Effects of Pasireotide Lar Therapy on Bone Metabolism

    Fondazione Policlinico Universitario Agostino Gemelli IRCCS 120 participants Est. completion 2028-06 1 site
    Other conditions: Acromegaly Due to Pituitary Adenoma, Acromegaly
    View official trial listing →
  • Completed NCT NCT00088582

    Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients

    Not yet reported Novartis Pharmaceuticals 62 participants 5 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00088595

    Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

    Not yet reported Novartis Pharmaceuticals 45 participants Est. completion 2008-07 4 sites Stand-alone
    Other conditions: Carcinoid Tumors
    View official trial listing →
  • Completed NCT NCT00088608

    A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease

    Not yet reported Novartis Pharmaceuticals 26 participants 5 sites
    Other conditions: Cushing's Syndrome
    View official trial listing →
  • Completed NCT NCT00171730

    An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

    Not yet reported Novartis Pharmaceuticals 30 participants Est. completion 2013-12-06 10 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00171951

    Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

    Not yet reported Novartis Pharmaceuticals 19 participants Est. completion 2013-07-08 8 sites Stand-alone
    Other conditions: Cushing Disease
    View official trial listing →
  • Completed NCT NCT00434148

    Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease

    Not yet reported Novartis Pharmaceuticals 162 participants Est. completion 2014-05 68 sites Stand-alone
    Other conditions: Cushing's Disease
    View official trial listing →
  • Completed NCT NCT00446082

    Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

    Not yet reported Novartis Pharmaceuticals 85 participants Est. completion 2013-11 17 sites Stand-alone
    Other conditions: Carcinoid Tumor, Acromegaly
    View official trial listing →
  • Completed NCT NCT00600886

    Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

    Not yet reported Novartis Pharmaceuticals 358 participants Est. completion 2016-03-11 95 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00690430

    Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

    Not yet reported Novartis Pharmaceuticals 186 participants Est. completion 2012-04 62 sites
    Other conditions: Symptomatic Refractory Resistant Carcinoid Disease
    View official trial listing →
  • Completed NCT NCT00698464

    Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

    Not yet reported Novartis Pharmaceuticals 34 participants 4 sites Stand-alone
    Other conditions: Hepatic Cirrhosis, Alcoholism
    View official trial listing →
  • Completed NCT NCT00804336

    Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

    Not yet reported Dana-Farber Cancer Institute 22 participants Est. completion 2015-04 3 sites Stand-alone
    Other conditions: Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
    View official trial listing →
  • Terminated NCT NCT00813592

    Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma

    Not yet reported University of Utah 2 participants Est. completion 2013-03 1 site
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT00859040

    Monthly SOM230C for Recurrent or Progressive Meningioma

    Not yet reported Patrick Y. Wen, MD 34 participants Est. completion 2016-01 8 sites Stand-alone
    Other conditions: Meningioma
    View official trial listing →
  • Terminated NCT NCT00929669

    Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

    Not yet reported University of Pennsylvania 2 participants Est. completion 2011-11 1 site Stand-alone
    Other conditions: Gonadotroph Adenomas
    View official trial listing →
  • Terminated NCT NCT00958841

    Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

    Not yet reported Novartis Pharmaceuticals 118 participants Est. completion 2015-06 42 sites Stand-alone
    Other conditions: Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
    View official trial listing →
  • Completed NCT NCT00994110

    Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

    Not yet reported Memorial Sloan Kettering Cancer Center 439 participants Est. completion 2014-09 1 site Stand-alone
    Other conditions: Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT01128192

    Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers

    Not yet reported Robert R. Henry, MD 45 participants Est. completion 2010-04 1 site Stand-alone
    Other conditions: Hyperglycemia
    View official trial listing →
  • Completed NCT NCT01137682

    Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

    Not yet reported Novartis Pharmaceuticals 198 participants Est. completion 2017-02-28 60 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Withdrawn NCT NCT01234974

    IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus

    Not yet reported Milton S. Hershey Medical Center Est. completion 2013-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01252251

    RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

    Not yet reported Memorial Sloan Kettering Cancer Center 14 participants Est. completion 2016-06 1 site Stand-alone
    Other conditions: Uveal Melanoma
    View official trial listing →
  • Completed NCT NCT01253161

    Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 29 participants Est. completion 2023-03-02 2 sites Stand-alone
    Other conditions: Neuroendocrine Tumors, Carcinoid Tumors
    View official trial listing →
  • Completed NCT NCT01263353

    Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

    Not yet reported Novartis Pharmaceuticals 36 participants Est. completion 2014-03 4 sites Stand-alone
    Other conditions: Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
    View official trial listing →
  • Completed NCT NCT01270321

    Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer

    Not yet reported Emory University 42 participants Est. completion 2019-02 3 sites Stand-alone
    Other conditions: Thyroid Cancer
    View official trial listing →
  • Completed NCT NCT01283542

    Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.

    Not yet reported Novartis Pharmaceuticals 20 participants Est. completion 2017-09-12 7 sites Stand-alone
    Other conditions: Non-functioning Pituitary Adenoma
    View official trial listing →
  • Terminated NCT NCT01313559

    Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 6 participants Est. completion 2012-11-29 2 sites Stand-alone
    Other conditions: Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer
    View official trial listing →
  • Withdrawn NCT NCT01329289

    SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

    Not yet reported University of Pittsburgh Est. completion 2012-02 1 site
    Other conditions: Multiple Myeloma in Relapse, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01356862

    Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer

    Not yet reported Alliance Pour La Recherche en Cancerologie 91 participants Est. completion 2013-01 2 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01364415

    Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

    Not yet reported Novartis Pharmaceuticals 29 participants Est. completion 2016-04 4 sites Stand-alone
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Terminated NCT NCT01372618

    Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor

    Not yet reported, Not yet reported NYU Langone Health 9 participants Est. completion 2015-10 1 site Stand-alone
    Other conditions: Ductal Carcinoma in Situ
    View official trial listing →
  • Completed NCT NCT01372644

    Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

    Not yet reported NYU Langone Health 15 participants Est. completion 2013-11 1 site Stand-alone
    Other conditions: Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS), Atypical Lobular Hyperplasia (ALH) of Breast
    View official trial listing →
  • Terminated NCT NCT01374451

    Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

    Not yet reported Novartis Pharmaceuticals 160 participants Est. completion 2015-02 47 sites Stand-alone
    Other conditions: Islet Cell Tumor
    View official trial listing →
  • Completed NCT NCT01374906

    Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

    Not yet reported Novartis Pharmaceuticals 150 participants Est. completion 2016-12-21 82 sites Stand-alone
    Other conditions: Cushing's Disease
    View official trial listing →
  • Completed NCT NCT01385956

    SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 20 participants Est. completion 2014-11 1 site
    Other conditions: Pancreatic Cancer
    View official trial listing →
  • Status unknown NCT NCT01417806

    Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer

    Not yet reported South Florida Veterans Affairs Foundation for Research and Education 28 participants Est. completion 2016-12 1 site
    Other conditions: Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT01434069

    Phase I Trial of Combination of FOLFIRI and SOM 230

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 16 participants Est. completion 2015-12 1 site
    Other conditions: Gastrointestinal Tumor
    View official trial listing →
  • Completed NCT NCT01468532

    Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

    Not yet reported, Not yet reported Barbara Ann Karmanos Cancer Institute 18 participants Est. completion 2017-07-20 1 site Stand-alone
    Other conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
    View official trial listing →
  • Completed NCT NCT01469572

    Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

    Not yet reported Emory University 13 participants Est. completion 2018-10 1 site Stand-alone
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT01488487

    Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

    Not yet reported UNC Lineberger Comprehensive Cancer Center 24 participants Est. completion 2015-03 3 sites Stand-alone
    Other conditions: Advanced Adult Hepatocellular Carcinoma
    View official trial listing →
  • Completed NCT NCT01563354

    3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial

    Not yet reported Novartis Pharmaceuticals 124 participants Est. completion 2020-02-10 36 sites Stand-alone
    Other conditions: Neuroendocrine Carcinoma of the Lung and Thymus
    View official trial listing →
  • Completed NCT NCT01578928

    A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers

    Not yet reported Novartis Pharmaceuticals 50 participants Est. completion 2014-05 2 sites
    Other conditions: Renal Impairment
    View official trial listing →
  • Completed NCT NCT01582061

    An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.

    Not yet reported Novartis Pharmaceuticals 104 participants Est. completion 2017-01-26 65 sites Stand-alone
    Other conditions: Cushing's Disease
    View official trial listing →
  • Completed NCT NCT01590199

    Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

    Not yet reported Novartis Pharmaceuticals 18 participants Est. completion 2018-09-11 3 sites
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Terminated NCT NCT01617733

    Pasireotide Therapy in Patients With Nelson's Syndrome

    Not yet reported Sheffield Teaching Hospitals NHS Foundation Trust 8 participants Est. completion 2015-12 4 sites Stand-alone
    Other conditions: Nelson Syndrome
    View official trial listing →
  • Completed NCT NCT01620138

    Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas

    Not yet reported, Not yet reported Universidade Federal do Rio de Janeiro 21 participants Est. completion 2012-06 1 site
    Other conditions: Non-functioning Pituitary Adenomas, Prolactinomas
    View official trial listing →
  • Completed NCT NCT01625520

    SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer

    Not yet reported Federico II University 19 participants 1 site Stand-alone
    Other conditions: Medullary Thyroid Cancer
    View official trial listing →
  • Completed NCT NCT01637272

    Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome

    Not yet reported Novartis Pharmaceuticals 43 participants Est. completion 2015-08-07 17 sites Stand-alone
    Other conditions: Dumping Syndrome
    View official trial listing →
  • Completed NCT NCT01639352

    Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma

    Not yet reported Lynn Feun 20 participants Est. completion 2017-02 1 site
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Completed NCT NCT01646684

    Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer

    Not yet reported Novartis Pharmaceuticals 9 participants Est. completion 2018-11-13 4 sites
    Other conditions: Castration Resistant Prostate Cancer
    View official trial listing →
  • Completed NCT NCT01652547

    A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma

    Not yet reported Novartis Pharmaceuticals 10 participants Est. completion 2015-04 3 sites Stand-alone
    Other conditions: Metastatic Melanoma and Merkel Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT01670110

    Pasireotide LAR in Severe Polycystic Liver Disease

    Not yet reported Mayo Clinic 48 participants Est. completion 2018-09 1 site
    Other conditions: Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney Disease, Autosomal Dominant Polycystic Liver Disease
    View official trial listing →
  • Completed NCT NCT01673646

    Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

    Not yet reported Novartis Pharmaceuticals 33 participants Est. completion 2017-04-10 27 sites Stand-alone
    Other conditions: Acromegaly, Pituitary Gigantism
    View official trial listing →
  • Completed NCT NCT01794793

    Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

    Not yet reported RECORDATI GROUP 337 participants Est. completion 2023-07-25 94 sites Stand-alone
    Other conditions: Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS
    View official trial listing →
  • Completed NCT NCT01895296

    Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping Syndrome

    Not yet reported Universitaire Ziekenhuizen KU Leuven 9 participants Est. completion 2010-01 1 site Stand-alone
    Other conditions: Postoperative Dumping Syndrome
    View official trial listing →
  • Terminated NCT NCT01915303

    Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

    Not yet reported Novartis Pharmaceuticals 68 participants Est. completion 2019-09-04 29 sites Stand-alone
    Other conditions: Cushings Disease
    View official trial listing →
  • Approved For Marketing NCT NCT01995734

    An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly

    Novartis Pharmaceuticals 37 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT02021942

    Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

    Not yet reported Prof. Dr. Berthold Schalke 16 participants Est. completion 2015-10 1 site
    Other conditions: Primary Inoperable Thymoma, Local Recurrent Thymoma
    View official trial listing →
  • Completed NCT NCT02048319

    Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Hepatic Cysts

    Not yet reported Radboud University Medical Center 34 participants Est. completion 2016-04 1 site Stand-alone
    Other conditions: Symptomatic Dominant Liver Cyst
    View official trial listing →
  • Completed NCT NCT02060383

    Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

    Not yet reported Novartis Pharmaceuticals 249 participants Est. completion 2018-03-26 43 sites Mixed
    Other conditions: Cushing's Disease, Acromegaly
    View official trial listing →
  • Completed NCT NCT02215070

    Pasireotide in Prevention of GI Toxicity

    Not yet reported Anthony Sung, MD 37 participants Est. completion 2019-10-15 2 sites Stand-alone
    Other conditions: Hematological Malignancies
    View official trial listing →
  • Completed NCT NCT02310269

    Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

    RECORDATI GROUP 152 participants Est. completion 2023-07-10 54 sites
    Other conditions: Cushings Disease
    View official trial listing →
  • Completed NCT NCT02354508

    Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

    Not yet reported Novartis Pharmaceuticals 123 participants Est. completion 2018-09-27 50 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT02527993

    Treatment of Hypoglycemia Following Gastric Bypass Surgery

    Not yet reported Zealand University Hospital 11 participants Est. completion 2017-04-08 Stand-alone
    Other conditions: Hypoglycemia, Obesity, Surgery
    View official trial listing →
  • Terminated NCT NCT02619617

    Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

    Not yet reported Novartis Pharmaceuticals 28 participants Est. completion 2018-09-25 4 sites
    Other conditions: Cluster Headache - Episodic and Chronic
    View official trial listing →
  • Completed NCT NCT02622906

    Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure

    Not yet reported Robert Benamouzig 24 participants Est. completion 2015-10 1 site
    Other conditions: Angiodysplasia
    View official trial listing →
  • Status unknown NCT NCT02668172

    Pasireotide LAR and Pegvisomant Study in Acromegaly

    Not yet reported Erasmus Medical Center 60 participants Est. completion 2017-06 1 site Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT02713776

    Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment

    Not yet reported Hospices Civils de Lyon 57 participants Est. completion 2021-01-08 14 sites Stand-alone
    Other conditions: Enterostomy
    View official trial listing →
  • Terminated NCT NCT02749227

    Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors

    Not yet reported Columbia University 4 participants Est. completion 2020-03-31 1 site Stand-alone
    Other conditions: Pituitary Tumor, ACTH-producing Pituitary Tumour
    View official trial listing →
  • Active, not recruiting NCT NCT02775227

    HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications

    Not yet reported Helsinki University Central Hospital 126 participants Est. completion 2029-12 1 site
    Other conditions: Pancreatic Fistula, Pancreatic Neoplasms
    View official trial listing →
  • Withdrawn NCT NCT02779257

    Pasireotide Treatment for Neuroendocrine Tumor

    Not yet reported University of Maryland, Baltimore Est. completion 2016-06 Stand-alone
    Other conditions: Gastro-enteropancreatic Neuroendocrine Tumor
    View official trial listing →
  • Withdrawn NCT NCT02780882

    SOM230 Ectopic ACTH-producing Tumors

    Not yet reported Cedars-Sinai Medical Center Est. completion 2019-06 1 site Stand-alone
    Other conditions: Ectopic ACTH Syndrome
    View official trial listing →
  • No Longer Available NCT NCT02835131

    Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia

    Montefiore Medical Center 1 site
    Other conditions: Congenital Hyperinsulinism
    View official trial listing →
  • Withdrawn NCT NCT03053284

    Pasireotide in Hyperinsulinemic Hypoglycemia

    Not yet reported Montefiore Medical Center Est. completion 2018-04 Stand-alone
    Other conditions: Congenital Hyperinsulinism, Insulinoma, Hyperinsulinism
    View official trial listing →
  • Completed NCT NCT03080181

    Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment

    Not yet reported University of Palermo 24 participants Est. completion 2017-01-28 Stand-alone
    Other conditions: Cushing Disease
    View official trial listing →
  • Completed NCT NCT03103009

    Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia

    Not yet reported University of Colorado, Denver 1 participants Est. completion 2017-12-22 1 site Stand-alone
    Other conditions: Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia
    View official trial listing →
  • Status unknown NCT NCT03514576

    Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery

    Not yet reported Zealand University Hospital 5 participants Est. completion 2018-11-01 1 site Stand-alone
    Other conditions: Hypoglycemia, Reactive
    View official trial listing →
  • Completed NCT NCT03847207

    A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310

    Not yet reported Nxera Pharma UK Limited 42 participants Est. completion 2020-03-05 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT03972488

    Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

    Not yet reported Advanced Accelerator Applications 226 participants Est. completion 2027-10-29 40 sites
    Other conditions: Gastro-enteropancreatic Neuroendocrine Tumor
    View official trial listing →
  • Completed NCT NCT04281680

    Impact of Pasireotide on Postoperative Pancreatic Fistulas Following Distal Resections

    Helsinki University Central Hospital 258 participants Est. completion 2016-04-30
    Other conditions: Surgical Complications
    View official trial listing →
  • Terminated NCT NCT04826432

    Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis

    Not yet reported Gustave Roussy, Cancer Campus, Grand Paris 6 participants Est. completion 2024-02-07 1 site Stand-alone
    Other conditions: Peritoneal Carcinomatosis
    View official trial listing →
  • Active, not recruiting NCT NCT05928390

    Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

    Not yet reported RECORDATI GROUP 93 participants Est. completion 2026-04 29 sites Stand-alone
    Other conditions: Post-Bariatric Hypoglycemia
    View official trial listing →
  • Completed NCT NCT07312643

    Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule

    Not yet reported RECORDATI GROUP 40 participants Est. completion 2026-02-03 1 site Stand-alone
    Other conditions: Pharmacokinetics, Safety
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.